Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC

Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC

Episodes

Specialty:

All

Year:

All

EP. 1: Clinical Evaluation of ES-NSCLC in Japan

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 2: Determining Resectability in ES-NSCLC

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 3: Molecular Testing in Early-Stage NSCLC

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 4: Testing for EGFR in NSCLC Worldwide

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 5: Standard of Care for EGFR+ ES-NSCLC

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 6: Adjuvant Approaches in EGFR+ NSCLC

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 7: Unprecedented Results from ADAURA

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 8: Practical Implications of ADAURA in NSCLC

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

EP. 9: Paradigm Shift for Early EGFR+ NSCLC

ByMasahiro Tsuboi, MD, National Cancer Center Hospital East,David Planchard, MD, PhD,Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management